Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director of Campus Operations - Administration and Finance 2021. All Rights Reserved. A California State University CampusExecutive Director of Campus Operations - Administration and FinanceVallejo, CaliforniaThe Administration and Finance Division plays a vital role in supporting the university’s operational backbone, encompassing areas such as finance, budgeting, facilities, public safety, environmental health and safety, procurement, University Housing, Information Technology Services, Performing Arts Center, Cal Poly Partners, and divisional operations. The SVP of Administration and Finance reports directly to the University President and serves as a member of the President’s Cabinet, working collaboratively with other university divisions to advance strategic initiatives, ensure financial sustainability, and maintain a safe, inclusive, and well-functioning campus environment.
Executive Director, Targeting, Optimization, & Measurement Analytical Suite Genentech IncExecutive Director, Targeting, Optimization, & Measurement Analytical SuiteSouth San Francisco, CA$236,900–$439,900 / yearAs a strategic commercial analytics leader, the Executive Director of Targeting, Optimization, & Measurement in Insights & Analytics drives the vision, design, and execution of scalable advanced analytics capabilities across the organization-such as Next Best Action, Customer Orchestration, resource optimization, and measurement. Measurement: Build measurement frameworks for analytics and AI solutions, including success metrics, test-and-learn design, adoption tracking, performance monitoring, and outcome measurement to quantify business, scientific, operational, and patient impact.
Executive Director, Clinical Development Revolution MedicinesExecutive Director, Clinical DevelopmentRedwood City, California$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. In this critical role, you will be responsible for developing the strategic plans and ensuring efficient operational execution of the molecule(s)’ clinical development program in one or more disease indications, from early-stage studies to regulatory submissions and potential commercialization.
US Distribution Executive Director Genentech IncUS Distribution Executive DirectorSouth San Francisco, CA$232,900–$432,500 / yearTechnical Skills: Extensive experience managing multi-node networks, cold chain/temperature-sensitive products, 3PL management (RFPs, contracts, SLAs), and SAP enterprise systems (TMS/EWM). As the US Distribution Executive Director, you are accountable for day-to-day operations and strategic oversight to ensure a safe, compliant, cost-effective, and resilient US Distribution Network that supports market demands and meets evolving customer expectations.
NewExecutive Director, Computational Systems Biology Revolution MedicinesExecutive Director, Computational Systems BiologyRedwood City, California$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. Cross-functional collaboration across research, translational, development and medical affairs groups: Work across functions to support advancement of programs from early discovery into clinical development using biological insights derived from computational approaches.
Executive Director, Clinical Development Revolution Medicines IncExecutive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director / Vice President, Biology & Translational Pharmacology ProfluentExecutive Director / Vice President, Biology & Translational PharmacologyEmeryville, CA$270,000–$340,000 / yearProvide accountable leadership for cross-functional therapeutic program teams, integrating translational biology, genome editing, protein engineering, delivery, pharmacology, bioanalytics, CMC, regulatory, and preclinical development expertise. Founded in 2022 and headquartered in Emeryville, CA, Profluent is backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures and has raised over $150M to date.
NewExecutive Director, Clinical Supply Chain Revolution MedicinesExecutive Director, Clinical Supply ChainRedwood City, California$265,000–$331,000 / yearLeveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Early Clinical Development Revolution Medicines IncExecutive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Computational Systems Biology Revolution Medicines IncExecutive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines IncExecutive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director of Campus Operations - Administration and Finance Cal PolyExecutive Director of Campus Operations - Administration and FinanceVallejo, CaliforniaThe Administration and Finance Division plays a vital role in supporting the university’s operational backbone, encompassing areas such as finance, budgeting, facilities, public safety, environmental health and safety, procurement, University Housing, Information Technology Services, Performing Arts Center, Cal Poly Partners, and divisional operations. The SVP of Administration and Finance reports directly to the University President and serves as a member of the President’s Cabinet, working collaboratively with other university divisions to advance strategic initiatives, ensure financial sustainability, and maintain a safe, inclusive, and well-functioning campus environment.
Executive Director, Global Commercial Lead Revolution Medicines, Inc.Executive Director, Global Commercial LeadRedwood City, CA$252,000–$315,000 / yearThe Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Global Commercial Lead Revolution MedicinesExecutive Director, Global Commercial LeadRedwood City, CaliforniaReporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS.
Executive Director, Patents Revolution MedicinesExecutive Director, PatentsRedwood City, California$315,000–$362,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role will function as a key strategic partner to the VP and a trusted advisor to senior leadership, with a primary focus on strengthening the durability and value of company assets worldwide, anticipating competitive threats, and identifying and mitigating vulnerabilities.
Executive Director, Global Commercial Lead Revolution Medicines IncExecutive Director, Global Commercial LeadRedwood City, CA$265,000–$331,000 / yearThe Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Sourcer Zoox IncExecutive SourcerFoster City, CA$123,000–$161,000 / yearBusiness Acumen: Ability to quickly understand a broad range of domains (Autonomy, Hardware, Software, G&A, Operations) and articulate how a leader fits into the broader business strategy. You will develop recruitment strategies, create data-driven market maps, and uncover passive leadership talent for our most critical Director, VP, and C-Suite roles.